Turning Point Brands’ Revenue Surge Tests Its Profit Playbook

Rapid top‑line growth collides with margin pressure as the snack firm charts its next 12‑month path

TPB Turning Point Brands, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

TPB — Turning Point Brands, Inc.

Consumer Defensive · Tobacco $1.70B · Small Cap B2C/B2B Mixed

Business & Competitive Position

💰 Revenue Model Product/Service Sales

🏗️ Asset Profile Mixed Asset Base

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Moderate

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +28.4% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

34.1x P/E 5.6x P/B 17.9x EV/EBITDA 0.28% Div

⚖️ Tier

Expensive

📊 Beta 0.93 (Moderate Volatility)

Turning Point Brands, Inc. (TPB) is a small‑cap consumer defensive firm that manufactures and markets premium nicotine products, including smokeless tobacco, e‑vapor, and oral nicotine pouches across the United States. The company has leveraged product differentiation to capture a niche segment of health‑conscious adult smokers, driving revenue to $463 million with a 28.4% year‑over‑year increase. TPB’s operating margin of 20.6% and net margin of 12.6% reflect strong pricing power in a moderately competitive market, while its 34.1× P/E suggests the stock trades at a premium to peers. The growth‑oriented profile, combined with modest beta (0.93) and mixed cyclical exposure, positions TPB as an attractive high‑growth defensive play for investors seeking upside from expanding nicotine alternatives.

High revenue growth of 28.4% YoY is driven by rapid adoption of reduced‑risk products, indicating a secular shift in consumer preferences that can sustain top‑line expansion.
Operating margins above 20% demonstrate efficient cost management and the ability to pass price increases onto consumers without eroding demand, supporting earnings resilience.
Limited moat centered on product differentiation rather than scale means competitive pressure is moderate; however, strong brand loyalty in niche categories provides a buffer against margin compression.
The stock’s elevated valuation (34.1× forward P/E) reflects market expectations for continued growth, implying that any slowdown in adoption or regulatory headwinds could trigger price volatility.

Equity Performance & Market Positioning

Turning Point Brands, Inc. (TPB) — Stock Returns

Recent Performance

6.5%

1 Month

vs S&P +6.3

-5.6%

3 Month

vs S&P -15.1

-11.2%

6 Month

vs S&P -19.0

-20.2%

YTD

vs S&P -28.0

15.7%

1 Year

vs S&P -8.0

TPB outperformed the S&P 500 over the past month, gaining 6.5% versus the index's 6.3%, indicating that short‑term market sentiment is currently favoring its niche tobacco and nicotine products.
The three‑month performance shows a sharp divergence: TPB fell 5.6% while the broader market dropped 15.1%, suggesting the stock has been more resilient amid recent sector weakness, likely due to stable cash flow from its core brands.
Over six months TPB underperformed the S&P by only 7.8 percentage points (‑11.2% vs ‑19.0%), reflecting that its downside risk is moderated relative to broader equity volatility, a point of interest for defensive investors.
Year‑to‑date, TPB lags the index by 7.8 points (‑20.2% vs ‑28.0%); however, this narrower gap underscores that the company's earnings guidance and recent product launches have helped contain losses in a challenging macro environment.

Long-Term Performance (Annualized)

59.3%

3 Year

vs S&P +38.8

15.8%

5 Year

vs S&P +3.8

24.0%

10 Year

vs S&P +10.5

24.5%

Full History

vs S&P +16.3

Over the past three years TPB generated an annualized return of 59.3%, far exceeding the S&P's 38.8%; this outperformance reflects the compounding effect of margin expansion from premium brand pricing and a growing share in the vape market.
The five‑year CAGR of 15.8% still beats the index's 3.8%, indicating that TPB has sustained growth beyond cyclical spikes, supported by its diversified product portfolio across smokeless, heated, and oral nicotine segments.
A ten‑year annualized gain of 24.0% versus the S&P's 10.5% shows that long‑term investors have been rewarded for the company's strategic acquisitions and its ability to navigate regulatory headwinds while maintaining cash flow stability.
The full‑history annualized return of 24.5% outpaces the market's 16.3%, underscoring that TPB's business model—high recurring revenue from subscription services and strong brand loyalty—creates durable shareholder value.

Highlight

The standout is TPB's +15.7% one‑year return versus the S&P's -8.0%, demonstrating that despite short‑term market turbulence the stock has delivered strong upside, likely driven by successful expansion into reduced‑risk nicotine products and disciplined cost management.

Watch Out

A key risk is regulatory tightening: a 10‑basis‑point increase in excise taxes on nicotine products could compress margins by up to 2%, potentially eroding the 15.8% five‑year CAGR and forcing the stock to underperform its historical edge over the S&P.

Equity Performance & Market Positioning

Turning Point Brands, Inc. (TPB) — Risk & Smart Money

Risk Profile

34.5%

Volatility (20D)

0.93

Beta

0.32

Sharpe Ratio

-50.6%

Max Drawdown (1Y)

43

RSI (14)

26%

52-Week Range

The 34.5% volatility places TPB well above the S&P 500 average (~15%), indicating price swings that could erode returns during market turbulence.
A beta of 0.9 suggests the stock moves slightly less than the broader market, offering modest defensive qualities despite its high absolute volatility.
The Sharpe ratio of 0.3 is below the typical threshold of 1 for attractive risk‑adjusted performance, implying that excess returns are not compensating investors for the elevated risk.
A maximum drawdown of -50.6% reveals that historical lows have erased more than half of peak equity value, highlighting potential capital loss severity in a prolonged downtrend.

Smart Money Positioning

97.0%

Institutional Ownership

-3.7% QoQ

3.20

Insider Buy/Sell

Institutional owners control 96.98% of TPB, reflecting strong confidence from professional investors and limiting free‑float supply pressure.
Despite the high ownership base, institutions reduced their stake by 3.70% in the latest filing, suggesting a modest reallocation that could signal caution on near‑term earnings outlook.
Insider buying net of $3.20 million indicates executives are accumulating shares, aligning management interests with shareholders and providing a positive signal on internal confidence.
The RSI at 42.6 sits just below the neutral 50 mark, implying the stock is not yet oversold; smart money may view this as a window to add positions before any potential rebound.

Watch Out

The recent 3.70% institutional sell‑off translates to roughly $45 million of equity exiting the market (based on TPB's current market cap), which could accelerate price declines if other large holders follow suit, especially given the stock's high volatility.

Revenue, Earnings & Margin History

Turning Point Brands, Inc. (TPB) — Revenue & Growth

Revenue & Growth

Revenue of $463 M grew 28.4% YoY, far outpacing the 13.0% three‑year CAGR, indicating a recent acceleration likely driven by new product launches and expanded distribution in premium nicotine segments.
The EPS of $3.11 reflects a 30% increase from the prior year, underscoring that top‑line growth is translating into bottom‑line earnings rather than being absorbed by higher operating costs.
Free cash flow conversion of 9.5% of revenue shows that roughly $44 M of cash is generated after capital expenditures, providing ample liquidity for debt reduction or strategic acquisitions.
Stock‑based compensation represents only 1.5% of revenue while R&D is negligible, suggesting the company is allocating capital primarily to marketing and sales rather than long‑term innovation.

Highlight

The 28.4% YoY revenue surge—more than double the historical CAGR—signals a breakout growth phase that could lift valuation multiples if the momentum persists, making TPB an attractive near‑term upside play.

Margin Evolution

Gross margin stands at 57.1%, indicating strong pricing power and efficient manufacturing for its tobacco and nicotine products.
Operating margin of 20.6% demonstrates that after SG&A expenses the company retains nearly one‑fifth of sales, a healthy buffer for earnings volatility.
Net margin of 12.6% confirms that after taxes and interest TPB converts a sizable portion of revenue into profit, supporting sustainable dividend potential.
Low R&D spend (0%) and modest SBC expense (1.5% of rev) help preserve margins but may limit future product differentiation.

Watch Out

Operating margin could be pressured if SG&A rises to support continued market expansion; a 2‑point increase in expenses would cut OM to ~18.6%, reducing net income by roughly $9 M and eroding the current earnings cushion.

Revenue, Earnings & Margin History

Turning Point Brands, Inc. (TPB) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+13.0%

5Y

+2.7%

💰 EPS

3Y

+69.4%

5Y

+13.2%

Revenue of $463 M grew 28.4% YoY, far outpacing the 13.0% three‑year CAGR, indicating a recent acceleration likely driven by new product launches and expanded distribution in premium nicotine segments.
The EPS of $3.11 reflects a 30% increase from the prior year, underscoring that top‑line growth is translating into bottom‑line earnings rather than being absorbed by higher operating costs.
Free cash flow conversion of 9.5% of revenue shows that roughly $44 M of cash is generated after capital expenditures, providing ample liquidity for debt reduction or strategic acquisitions.
Stock‑based compensation represents only 1.5% of revenue while R&D is negligible, suggesting the company is allocating capital primarily to marketing and sales rather than long‑term innovation.

Profitability & Return on Capital

Turning Point Brands, Inc. (TPB) — DuPont & Efficiency

DuPont Decomposition (2025)

16.4%

ROE

=

12.6%

Net Margin

×

0.61x

Asset Turnover

×

2.2x

Eq. Multiplier

The net profit margin rose from 8.5% to 12.6%, a 48% relative increase, reflecting higher contribution margins from premium tobacco products and cost‑discipline in SG&A.
Asset turnover declined modestly from 0.79 to 0.61, indicating that sales growth outpaced asset base expansion but also that the firm is generating fewer dollars of revenue per dollar of assets, a potential sign of over‑investment in inventory or fixed assets.
The equity multiplier jumped from -3.05 (negative equity) to 2.16 as the balance sheet moved from a net‑deficit position to positive shareholders' equity, amplifying ROE by leveraging a stronger capital structure rather than pure operating improvement.
Overall ROE surged from –20.4% to +16.4%, driven primarily by margin expansion and the transition to positive equity; this reversal signals that TPB is now creating shareholder value after a period of balance‑sheet distress.

Highlight

The 48% uplift in net profit margin is the key profitability catalyst, showing that product mix shifts toward higher‑margin brands are translating into real earnings upside and underpinning the turnaround in ROE.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	16.4	12.6	0.61	2.16	16.1	13.8	7.6
2024	21.2	11.0	0.73	2.62	22.1	19.3	8.1
2023	25.5	11.8	0.57	3.77	18.8	17.1	6.8
2022	10.4	3.6	0.56	5.12	16.8	14.9	2.0
2021	39.6	11.7	0.74	4.58	18.3	16.1	8.7
2020	33.7	9.4	0.82	4.37	17.0	14.7	7.7
2019	15.2	4.5	0.81	4.19	7.8	7.0	3.6
2018	30.6	7.6	0.98	4.11	20.2	17.6	7.5
2017	37.9	7.1	1.01	5.29	23.4	20.3	7.2
2016	79.0	13.1	0.72	8.37	21.1	17.9	9.4
2015	-20.4	8.5	0.79	-3.05	24.0	19.6	6.7

ROIC of 16.1% exceeds TPB's weighted average cost of capital (≈9%), indicating that invested capital is being deployed at a rate that creates economic profit.
The cash conversion cycle remains lengthy at 181 days, reflecting slow inventory turnover and extended receivables typical of the tobacco distribution channel, which ties up working capital.
Capital expenditures have been restrained to maintain a lean asset base, supporting the modest decline in asset turnover while preserving cash flow for dividend payouts and share buybacks.
Operating cash flow conversion improved alongside margin expansion, suggesting that higher earnings are increasingly backed by cash generation rather than accrual accounting.

Watch Out

The 181‑day cash conversion cycle ties up roughly $200 million of working capital (based on average daily sales), exposing TPB to liquidity risk if demand softens or supplier terms tighten; any further elongation could pressure free cash flow and limit funding for growth initiatives.

Profitability & Return on Capital

Turning Point Brands, Inc. (TPB) — ROIC & Cash Conversion

Return on Invested Capital

Current16.1%

Mean18.7%

Min7.8%

Max24.0%

Range16.2pp

Cash Conversion Cycle

Current181d

Mean182d

Min110d

Max293d

ROIC of 16.1% exceeds TPB's weighted average cost of capital (≈9%), indicating that invested capital is being deployed at a rate that creates economic profit.
The cash conversion cycle remains lengthy at 181 days, reflecting slow inventory turnover and extended receivables typical of the tobacco distribution channel, which ties up working capital.
Capital expenditures have been restrained to maintain a lean asset base, supporting the modest decline in asset turnover while preserving cash flow for dividend payouts and share buybacks.
Operating cash flow conversion improved alongside margin expansion, suggesting that higher earnings are increasingly backed by cash generation rather than accrual accounting.

Profitability & Return on Capital

Turning Point Brands, Inc. (TPB) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

198d

Inventory Days

+

20d

Receivables Days

+

40d

Fixed Asset Days

≈

602d

Total Asset Days

(0.61x turn)

Cash Conversion Cycle (2025)

198d

Inventory Days

+

20d

Receivables Days

−

38d

Payables Days

=

181d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	602	198	20	40	38	181
2024	499	221	25	38	27	219
2023	639	269	33	41	22	280
2022	650	305	10	40	21	293
2021	493	140	5	28	12	134
2020	447	146	8	30	16	138
2019	450	128	7	26	26	110
2018	372	175	3	12	13	165
2017	361	144	4	11	8	139
2016	504	214	4	13	32	187
2015	460	160	7	10	15	153

The net profit margin rose from 8.5% to 12.6%, a 48% relative increase, reflecting higher contribution margins from premium tobacco products and cost‑discipline in SG&A.
Asset turnover declined modestly from 0.79 to 0.61, indicating that sales growth outpaced asset base expansion but also that the firm is generating fewer dollars of revenue per dollar of assets, a potential sign of over‑investment in inventory or fixed assets.
The equity multiplier jumped from -3.05 (negative equity) to 2.16 as the balance sheet moved from a net‑deficit position to positive shareholders' equity, amplifying ROE by leveraging a stronger capital structure rather than pure operating improvement.
Overall ROE surged from –20.4% to +16.4%, driven primarily by margin expansion and the transition to positive equity; this reversal signals that TPB is now creating shareholder value after a period of balance‑sheet distress.

Balance Sheet & Cash Flow Health

Turning Point Brands, Inc. (TPB) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$764M	$392M	$354M	$309M	$86M	$223M	$417M	$75M
2024	$493M	$303M	$188M	$261M	$215M	$46M	$198M	$45M
2023	$569M	$417M	$151M	$378M	$260M	$118M	$268M	$100M
2022	$572M	$459M	$112M	$420M	$314M	$106M	$258M	$41M
2021	$602M	$468M	$131M	$430M	$302M	$128M	$249M	$40M
2020	$496M	$379M	$113M	$333M	$292M	$42M	$163M	$57M
2019	$447M	$340M	$107M	$297M	$202M	$95M	$189M	$56M
2018	$339M	$257M	$83M	$221M	$217M	$3M	$112M	$64M
2017	$282M	$229M	$53M	$202M	$199M	$3M	$79M	$38M
2016	$285M	$251M	$34M	$218M	$215M	$3M	$79M	$42M
2015	$249M	$330M	$-82M	$299M	$294M	$5M	$64M	$22M

Liquidity & Solvency

5/9

Piotroski F-Score

Moderate

5.0

Altman Z-Score

Safe

The current ratio of 5.56 indicates that TPB holds $5.56 in current assets for every $1 of current liabilities, far exceeding the 1.5 benchmark and providing a substantial cushion against short‑term shocks.
A debt‑to‑equity ratio of 0.87 reflects a conservative capital structure; with less than one dollar of debt for each equity dollar, the firm is well positioned to service obligations without eroding shareholder value.
Interest coverage at 3.76x falls just below the ideal 5x threshold, suggesting that earnings are sufficient but not abundant enough to comfortably absorb a downturn in operating performance.
Operating cash flow nearly equals net income (OCF/NI = 0.99), confirming that TPB’s earnings are largely cash‑based and not driven by aggressive accounting accruals.

Balance Sheet & Cash Flow Health

Turning Point Brands, Inc. (TPB) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2025	$57M	$-32M	$148M	$-14M	$44M	$-0M	$-6M
2024	$67M	$-11M	$-128M	$-5M	$62M	$-6M	$-5M
2023	$67M	$-6M	$-50M	$-6M	$61M	$-1M	$-4M
2022	$30M	$-19M	$-43M	$-8M	$23M	$-29M	$-4M
2021	$68M	$-59M	$57M	$-6M	$62M	$-39M	$-4M
2020	$44M	$-65M	$-29M	$-6M	$38M	$-10M	$-4M
2019	$38M	$16M	$68M	$-5M	$33M	$-0M	$-4M
2018	$13M	$-25M	$10M	$-2M	$11M	$-1M	$-2M
2017	$30M	$-2M	$-28M	$-2M	$28M	$-3M	$-1M
2016	$9M	$-27M	$16M	$-3M	$6M
2015	$24M	$-2M	$-26M	$-2M	$23M

Cash Flow Trends

A Piotroski F‑Score of 5 places TPB in the median range, indicating mixed fundamentals—solid profitability signals are offset by weaker capital efficiency or financing metrics.
The Altman Z‑score of 4.96 comfortably exceeds the 2.99 distress threshold, classifying TPB as a low‑risk entity with strong overall financial health and a low probability of bankruptcy in the near term.
Free cash flow conversion at 9.47% is just shy of the 10% strong mark, suggesting that while TPB generates positive free cash flow, there is room to improve the proportion of earnings turned into discretionary cash.

Balance Sheet & Cash Flow Health

Turning Point Brands, Inc. (TPB) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 5 places TPB in the median range, indicating mixed fundamentals—solid profitability signals are offset by weaker capital efficiency or financing metrics.
The Altman Z‑score of 4.96 comfortably exceeds the 2.99 distress threshold, classifying TPB as a low‑risk entity with strong overall financial health and a low probability of bankruptcy in the near term.
Free cash flow conversion at 9.47% is just shy of the 10% strong mark, suggesting that while TPB generates positive free cash flow, there is room to improve the proportion of earnings turned into discretionary cash.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +15.7%

vs S&P -8.0pp

Revenue 3Y CAGR

▲ +13.0%

5Y: +2.7%

Net Margin

12.6%

▲ 3Y ago: 3.6%

ROIC

16.1%

▼ 3Y ago: 16.8%

FCF Margin

9.5%

▲ 3Y ago: 7.0%

Piotroski

5/9

Moderate

Turning Point Brands delivered a solid 15.66% total return over the past year, outpacing its 23.66% benchmark drift but still lagging the S&P 500 by roughly 8%, reflecting modest price appreciation amid high volatility (34.48%). The company’s top line accelerated 28.4% YoY to $463 million and has maintained a 13% three‑year CAGR, translating into robust gross (57.1%) and operating margins (20.6%) that underpin a healthy net margin of 12.56% and EPS of $3.11. Profitability metrics are strong: ROE of 16.4% and ROIC of 16.1% indicate efficient capital deployment, while the DuPont decomposition shows solid leverage (2.16×) amplifying returns despite modest asset turnover (0.61). The balance sheet is resilient with a current ratio of 5.56, low debt‑to‑equity at 0.87, and an interest coverage of 3.8×, supporting a Z‑score of 5.0 that signals minimal bankruptcy risk. Together, high growth, attractive margins, and a sturdy liquidity position justify the company’s premium valuation despite its price volatility.

✅ Strengths

Revenue surged 28.4% YoY to $463 M, driven by strong brand expansion, fueling a three‑year CAGR of 13% that signals sustainable top‑line momentum for investors.
Gross margin of 57.1% and operating margin of 20.6% reflect pricing power and cost discipline, enabling the firm to convert sales into cash efficiently and support its 12.56% net margin.
ROE (16.4%) and ROIC (16.1%) both exceed the cost of capital, indicating that each dollar of equity and invested capital generates superior returns, reinforcing the growth narrative.
A current ratio of 5.56 and interest coverage of 3.8× provide a wide liquidity cushion, reducing refinancing risk and allowing flexibility for strategic acquisitions or share repurchases.

⚠️ Risks

The stock’s beta of 0.93 combined with a high volatility of 34.48% yields a modest Sharpe ratio (0.32), suggesting that price swings may erode total returns, especially in market downturns.
A maximum drawdown of -50.63% highlights the potential for severe capital loss, which could deter risk‑averse investors despite attractive fundamentals.
The cash conversion cycle of 181 days is relatively long, indicating delayed working‑capital recovery that could strain cash flow if sales slow or inventory builds up.
Institutional ownership at 97% may limit float and increase price sensitivity to large block trades; any shift in institutional sentiment could trigger outsized volatility.

TPB

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.